BioSpace News Archive

According to the report, the global positron emission tomography scanners market was valued at US$ 915.5 Mn in 2019 and is projected to expand at a CAGR of 3% from 2020 to 2030.

Acetylcholine is a major neurotransmitter of the parasympathetic nervous system. It is an ester of choline and acetic acid and functions as a transmitter of nerve impulses within the central and peripheral nervous systems.

The surging cases of neurological disorders and traumatic brain injuries are the key factors boosting the global external ventricular drain market growth.

Loss of neutrophils causes disruption of immune defense mechanisms and increases the likelihood for infections. Neutropenia is frequently associated with cancer chemotherapy and developed by majority of cancer patients during chemotherapy.

Anti-infective agents are drugs used for the purpose of killing and/or suppressing the infection causing organisms from invading the host by means of its replication or releasing variety of toxins into the host.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2020.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its fina

Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announced today it will report results for the third quarter ended September 30, 2020 on Monday, November 9, 2020 after market close.

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. Forte intends to use the net proceeds of the offering for working

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter ended September 30, 2020 will be released after the close of market on Thursday, November 12, 2020. About Histogen Inc. Histogen Inc. is a clin